Here are the 10-K annual reports from Vera Therapeutics, Inc. (VERA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VERA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VERA filings page.
Vera Therapeutics is a late clinical-stage biotech focused on serious immunological kidney diseases, led by atacicept for IgA nephropathy (IgAN). In a pivotal Phase 3 trial, atacicept achieved a 46% reduction in proteinuria (UPCR) from baseline and a 42% reduction versus placebo at week 36 (p<0.0001), with a safety profile generally comparable to placebo and fewer serious adverse events.
The company has filed a Biologics License Application for atacicept in IgAN, which received FDA priority review with a PDUFA target action date of July 7, 2026. Vera is also advancing atacicept in other autoimmune kidney diseases through the ORIGIN EXTEND and PIONEER studies, MAU868 for BK virus in kidney transplant recipients, and VT-109, a next‑generation dual BAFF/APRIL inhibitor, all supported by a broad global IP and licensing strategy.